Biopharmaceutical company Provention Bio, Inc. announced that it has begun its Phase 1b/2a PREVAIL (PRV-3279 EVAluation In Lupus) study, a clinical trial evaluating PRV-3279. PRV-3279 is a treatment targeting the B-cells, which are responsible for the production of antibodies and autoantibodies (self-attacking antibodies). This treatment has the potential to prevent or minimize the effects of lupus and other B cell-related autoimmune diseases by suppressing the production of autoantibodies without wiping out the immune system’s healthy B-cells.

The PREVAIL study’s Phase 1b trial will test healthy volunteers, followed by a Phase 2a trial in which the treatment will be administered to participants with lupus. Results from Phase 1 are expected in the first half of 2020. Continue to follow Inside Lupus Research for updates on PRV-3279.

Read the announcement